The Serology Laboratory provides expertise and leadership on the development, validation, and standardization of serology assays for HPV and COVID-19 studies.
Both our HPV and COVID-19 teams create and improve tools that enable scientists to compare data across different vaccines and studies.
At the start of the COVID-19 pandemic in March, 2020, our scientists pivoted to evaluate the performance of SARS-CoV-2 antibody tests for the U.S. Food and Drug Administration. As the National Cancer Institute established the Serological Sciences Network that same year, our laboratory grew from its original HPV focus to address COVID-19 serology and immunology.
The Serology Laboratory combines the former HPV Immunology Laboratory and HPV Serology Laboratory, evolving from a legacy of expertise that stretches back more than two decades.
The HPV Immunology Laboratory was formed in 2001 under the direction of Ligia Pinto, Ph.D., with a mission to provide infrastructure and scientific leadership for studying immune responses to HPV infection and vaccines in large epidemiological cohorts. In response to developments in the field and the need to increase HPV vaccine implementation worldwide, we worked with the National Cancer Institute, Centers for Disease Control and Prevention, the Bill and Melinda Gates Foundation, and various other collaborators to identify gaps in the HPV serology field. In response, the HPV Serology Laboratory was established in January 2017.